+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Gastrointestinal Stromal Tumor GIST is a type of soft tissue tumor that forms in the digestive system, often in the stomach or small intestine, caused by changes in certain proteins leading to uncontrolled cell growth. This research is evaluating the drug velzatinib GSK6042981 in adults with newly diagnosed metastatic or unresectable GIST, comparing it to the standard treatment imatinib to see if it can delay disease progression and assess safety and tolerability. Participants will be randomly assigned to receive either velzatinib or imatinib, with treatments given according to study protocols. The study will monitor each participant over time to compare the effects of these medications on tumor growth and patient health. Throughout the trial, participants will undergo regular assessments including imaging scans reviewed by independent central review, evaluations of tumor response, survival tracking, safety monitoring of side effects and vital signs, and quality of life questionnaires. The study will last for up to approximately 74 to 75 months, with ongoing evaluations to measure progression-free survival and other important outcomes.

Age: 18Years +All GendersPhase 3
93 locations
A

Actively Recruiting

Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.

Age: 18Years +All GendersPhase Not Applicable
55 locations
S

Actively Recruiting

Researchers are evaluating the use of doxycycline, an older and affordable antibiotic, to target cancer stem cells in patients with early-stage estrogen receptor positive ER and human epidermal growth factor receptor 2-negative HER2- breast cancer. These cancer stem cells are believed to cause treatment resistance and cancer recurrence, and the study aims to see if doxycycline can improve patients response to standard neoadjuvant chemotherapy. This is a phase II, open-label clinical trial focusing on this specific breast cancer subtype with low rates of complete tumor response to current treatments. Participants will receive neoadjuvant chemotherapy consisting of four cycles of epirubicin and cyclophosphamide every three weeks, followed by 12 weekly doses of paclitaxel. Alongside chemotherapy, doxycycline will be given orally at a dose of 200 mg per day from day 5 to day 18 of each chemotherapy cycle. The study will analyze tumor samples before and after treatment to assess changes in cancer stem cell markers and measure pathological response to treatment. During the trial, participants will undergo tumor biopsies and surgery after completing chemotherapy. Researchers will assess the presence of ALDH1, a marker of cancer stem cells, and evaluate pathological complete response by checking for any remaining invasive cancer in the breast and lymph nodes. Additional measures include tumor shrinkage on imaging, patient adherence to doxycycline, and patient-reported treatment burden. The study monitors safety and treatment effects up to 30 days after the last treatment dose, with a total participation period spanning from registration through surgery and follow-up assessments.

Age: 18Years +All GendersPhase 2
8 locations